Anti-FcλRIV [9E9]
Invented at The Rockefeller University
- Datasheet
- References (2)
- Inventor Info
Info
![Image for Anti-FcλRIV [9E9]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,q_auto/26dbb14c-ddcc-4ee1-9f4f-8121cbe0cb5f.jpg)
![Image for Anti-FcλRIV [9E9]](https://res.cloudinary.com/ximbio/image/upload/c_limit,fl_lossy,h_282,q_auto,w_368/26dbb14c-ddcc-4ee1-9f4f-8121cbe0cb5f.jpg)
![Image thumbnail for Anti-FcλRIV [9E9]](https://res.cloudinary.com/ximbio/image/upload/c_fit,fl_lossy,h_45,q_auto/26dbb14c-ddcc-4ee1-9f4f-8121cbe0cb5f.jpg)
| Applications | FACS IHC |
| Antigen/Gene or Protein Targets | FcγRIV |
| Reactivity | Mouse |
| Relevance | FcγR recognises the constant domain of IgG antibodies. FcγRIV, also known as CD16-2, is an intermediate-affinity activating receptor for IgG2a and IgG2b. It is expressed on peripheral blood leukocytes, spleen, thymus, colon, and the intestine. |
| Host | Mouse |
| Immunogen | FcγRIV extracellular domain fused with IgG1 Fc |
| Subclass | IgG |
| Research Area | Cell Type or Organelle Marker, Immunology |
References: 2 entries
Nimmerjahn et al. 2010. Proc Natl Acad Sci U S A. 107(45):19396-401. PMID: 20974962.
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo.
Europe PMC ID: 20974962
Add a reference
References: 2 entries
Nimmerjahn et al. 2010. Proc Natl Acad Sci U S A. 107(45):19396-401. PMID: 20974962.
FcγRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo.
Add a reference
